First AD

Second AD

Panelists discuss how for patients with chronic myeloid leukemia who develop the T315I mutation, ponatinib and asciminib have demonstrated efficacy in the PACE and ASCEMBL trials, respectively, with ponatinib showing a major cytogenetic response rate in patients with T315I mutation and asciminib demonstrating superior major molecular response vs bosutinib.

Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

Video content above is prompted by the following:

We know that a T315I mutation in the kinase domain confers resistance to our frontline therapies for chronic myeloid leukemia (bosutinib, dasatinib, imatinib, and nilotinib). What therapies are available for patients who develop this mutation while taking their first-line tyrosine kinase inhibitor?

Please briefly review the ASCEMBL and PACE trials and key outcomes.

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 